Cargando…
Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Glucocorticoids have been the primary treatment of graft-versus-host disease (GVHD) over the past decade. Complete responses to steroid therapy are usually expected in almost one-third of aGVHD cases and partial response is anticipated in another one-third of patients. However, for those patients no...
Autores principales: | Nassar, Amr, Elgohary, Ghada, Elhassan, Tusneem, Nurgat, Zubeir, Mohamed, Said Y., Aljurf, Mahmoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227326/ https://www.ncbi.nlm.nih.gov/pubmed/25405023 http://dx.doi.org/10.1155/2014/980301 |
Ejemplares similares
-
P788: OUTCOME OF SEVERE APLASTIC ANEMIA TREATED WITH ALLOGENIC STEM CELL TRANSPLANTATION COMPARED WITH IMMUNOSUPPRESSIVE THERAPY AS FIRST LINE.
por: Haroon, Alfadil, et al.
Publicado: (2023) -
Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease
por: van Lier, Yannouck F., et al.
Publicado: (2023) -
The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021) -
P1420: COMPARATIVE STUDY OF CYCLOSPORINE VERSUS TACROLIMUS IN ADDITION TO METHOTREXATE AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN MATCHED SIBLING ALLOGENEIC STEM CELL TRANSPLANTATION OF SICKLE CELL DISEASE
por: Alfaqawi, Samar, et al.
Publicado: (2023) -
Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors
por: Perez, Lia Elena, et al.
Publicado: (2016)